16 September 2026 editorial review · Trial
DFMO in recent-onset T1D: phase 1 safety study: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Added historical trial from the current registry and primary publication; distinguished enrollment/analysis populations, study endpoints, benefit limits and program status. The 2023 paper reports 41 participants randomized approximately 3:1 and says the primary safety/tolerability endpoint was met. Higher-dose C-peptide findings were exploratory; this small study does not establish clinical efficacy. The registry has no posted results tables.
Sources: DFMO in Children With Type 1 Diabetes; Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes.
Limits: Editorial source comparison, not independent clinical certification. A completed trial is not a currently recruiting option.